Seeking Alpha

NPS Pharmaceuticals, Inc. (NPSP)

  • LaboMedic | Send Message 26 Jan

    $NPSP Wedbush Reiterates Neutral On NPS Pharmaceuticals Despite FDA Approval For Natpara
      • LaboMedic | Send Message 18 Jan

        Analyst Highlights - Week 3 - Healthcare (Part III) $AGIO $ICPT $NPSP $HZNP
          • LaboMedic | Send Message 13 Jan

            $NPSP Oppenheimer Comments On NPS Pharma In Light Of Shire Takeover
              • Jim Van Meerten | Send Message 12 Jan

                BACHART MORNING CALL 1/12 $AA, $BMY, $NPSP
                  • Capitalist Bull | Send Message 12 Jan

                    It's a shame $NPSP got bought out. Company head great potential to be a big winner during the next big rally.
                      • mstar991 | Send Message 12 Jan

                        $NPSP takeover at 46 !
                          • bgold1955 | Send Message 11 Jan

                            Shire to purchase $NPSP for estimated $46 per share.
                              • Balanced Investor | Send Message 17 Dec 2014

                                $NPSP may be takeover target for $SHPG; Benzinga confirmed filed 8-K shows multi billion $ loan after failed bid for $MRK
                                Reply (1)
                                • ksualum98 | Send Message 12 Jan
                                  : Good call!
                                  • Life Sciences Report | Send Message 11 Dec 2014

                                    Wedbush Securities' David Nierengarten On Genetic Cures For Disease: Impossible Dream... $AGTC, $BLUE, $NPSP
                                      • BiotechX | Send Message 18 Nov 2014

                                        $NPSP with a PT of $40. 2015 will be a good year for this stock.
                                          Visit Seeking Alpha's
                                          NPSP vs. ETF Alternatives
                                          Company Description
                                          NPS Pharmaceuticals Inc is involved in the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs.
                                          Sector: Healthcare
                                          Industry: Biotechnology
                                          Country: United States